Sign in →

Test ID: LIPA Lipoprotein (a), Serum

Reporting Name

Lipoprotein (a), S

Useful For

Cardiovascular disease (CVD) risk refinement in patients with moderate or high risk based on conventional risk factors

Specimen Type


Specimen Required

Patient Preparation: Fasting-overnight (12-14 hours)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 7 days
  Frozen  7 days

Reference Values

≤30 mg/dL

Values >30 mg/dL may suggest increased risk of coronary heart disease.


For SI unit Reference Values, see

Day(s) and Time(s) Performed

Monday through Saturday; Continuously

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
LIPA Lipoprotein (a), S 10835-7


Result ID Test Result Name Result LOINC Value
LIPA Lipoprotein (a), S 10835-7

Clinical Information

Lipoprotein (a) (Lp[a]) consists of an LDL particle that is covalently bound to an additional protein, apolipoprotein (a) (Apo[a]). Apo(a) has high-sequence homology with the coagulation factor plasminogen and, like LDL, Lp(a) contains apolipoprotein B100 (ApoB). Thus, Lp(a) is both proatherogenic and prothrombotic. Lp(a) is an independent risk factor for coronary heart disease (CHD), ischemic stroke, and aortic valve stenosis. Lp(a) has been referred to as "the most atherogenic lipoprotein." The mechanism of increased risk is unclear but most likely involves progression of atherosclerotic stenosis via intimal deposition of cholesterol and promotion of thrombosis via homology to plasminogen.


Concentrations of Lp(a) particles in the blood can be expressed readily by 2 methods: as concentrations of Lp(a) protein or as Lp(a) cholesterol. Mayo’s Cardiovascular Laboratory Medicine measures and reports Lp(a) cholesterol individually (LPAWS / Lipoprotein [a] Cholesterol, Serum) and as a part of the lipoprotein profile (LMPP / Lipoprotein Metabolism Profile). The cholesterol content of Lp(a) particles varies little, and Lp(a) can contain significant proportions of the serum cholesterol.


Unlike Lp(a) cholesterol, accurate immunochemical measurement of Lp(a)-specific protein, is complicated by the heterogeneity of Lp(a) molecular size. Due to the large number of polymorphisms in the population any given individual can have an Apo(a) protein between 240 to 800 kDa. This heterogeneity leads to inaccuracies when results are expressed in terms of mg/dL of protein. In addition, the degree of atherogenicity of the Lp(a) particle may depend on the molecular size of the Lp(a)-specific protein.


Serum concentrations of Lp(a) are related to genetic factors, and are largely unaffected by diet, exercise and lipid-lowering pharmaceuticals. However, in a patient with additional modifiable CHD risk factors, more aggressive therapy to normalize these factors may be indicated if the Lp(a) value is also increased.


The frequency distribution of serum lipoprotein (a) (Lp[a]) concentrations is markedly skewed toward the low end, with approximately 85% of the population having concentrations <30 mg/dL.


Lp(a) concentrations >30 mg/dL are associated with 2- to 3-fold increased risk of cardiovascular events independent of conventional risk markers.

Clinical Reference

1. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009 Jul 22;302(4):412-423

2. Lackner C, Cohen JC, Hobbs HH: Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2:933-940

3. Albers JJ, Slee A, O'Brien KD, et al: Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013 Oct 22;62(17):1575-1579

4. Erqou S, Thompson A, Di Angelantonio E, et al: Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010 May 11;55(19):2160-2167

Analytic Time

Same day/1 day

Method Name

Automated Turbidimetric Immunoassay


If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (

Mayo Medical Laboratories | Cardiology Catalog Additional Information: